BRIEF—Ardelyx lifted by better data from second Phase III trial

Ardelyx has released positive Phase III data from T3MPO-2, the firm’s second Phase III trial of tenapanor for irritable bowel syndrome with constipation (IBS-C).

The data show 36.5% of the test group, compared to 23.7% of the placebo arm, experienced benefit including at least a 30% reduction in abdominal pain.

The company says it will file for regulatory approval in this indication in the USA in the latter half of next year.